GSK 3277511A

Drug Profile

GSK 3277511A

Alternative Names: GSK3277511; GSK3277511A; NTHi/Mcat-vaccine

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory tract disorders

Most Recent Events

  • 30 Jun 2017 GlaxoSmithKline initiates enrolment in a phase I trial in Healthy volunteers in Belgium before June 2017(NCT03201211)
  • 31 Mar 2017 GlaxoSmithKline completes a phase I trial in Respiratory tract disorders (Prevention) in Belgium (IM) (NCT02547974)
  • 01 Aug 2015 Phase-I clinical trials in Respiratory tract disorders (Prevention) in Belgium (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top